Bio-Gene Technology Ltd
ASX:BGT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bio-Gene Technology Ltd
Common Shares Outstanding
Bio-Gene Technology Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bio-Gene Technology Ltd
ASX:BGT
|
Common Shares Outstanding
AU$305.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Nufarm Ltd
ASX:NUF
|
Common Shares Outstanding
AU$383m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Parkway Corporate Ltd
ASX:PWN
|
Common Shares Outstanding
AU$2.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
25%
|
|
|
Terragen Holdings Ltd
ASX:TGH
|
Common Shares Outstanding
AU$505m
|
CAGR 3-Years
38%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Trigg Mining Ltd
ASX:TMG
|
Common Shares Outstanding
AU$931.3m
|
CAGR 3-Years
74%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
R
|
RLF AgTech Ltd
ASX:RLF
|
Common Shares Outstanding
AU$371.9m
|
CAGR 3-Years
26%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Bio-Gene Technology Ltd
Glance View
Bio-Gene Technology Ltd. is a development company enabling the next generation of novel insecticides, addressing the problems of insecticide resistance and toxicity. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-29. The Company’s principal activity is to develop and commercialize insecticide products. The company is focused on enabling novel insecticides to address the global problem of insecticide resistance and toxicity. Its novel platform technology is based on naturally occurring beta-triketones. The Company’s lead beta-triketone insecticide products include Flavocide and Qcide. Flavocide is a synthetically produced nature-identical compound. Testing of Flavocide has been undertaken and continues to be performed by both government research laboratories as well as by commercial collaborators. Qcide natural oil with high levels of tasmanone. The oil is extracted from the leaves of the Gympie Messmate, by utilizing a steam distillation process.
See Also
What is Bio-Gene Technology Ltd's Common Shares Outstanding?
Common Shares Outstanding
305.1m
AUD
Based on the financial report for Dec 31, 2025, Bio-Gene Technology Ltd's Common Shares Outstanding amounts to 305.1m AUD.
What is Bio-Gene Technology Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
15%
Over the last year, the Common Shares Outstanding growth was 51%. The average annual Common Shares Outstanding growth rates for Bio-Gene Technology Ltd have been 20% over the past three years , 15% over the past five years .
